Turkish Real Life Atrial Fibrillation in Clinical Practice: TRAFFIC Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karabay Can Yücel, Taşolar Hakan, Ülgen Kunak Ayşegül, Çap Murat, Astarcıoğlu Mehmet Ali, Şen Taner, Kaplan Mehmet, Coşgun Muharrem Said, Vatansever Ağca Fahriye, Arslan Uğur, Açıksarı Gönül, Er Fahri, Mert Kadir Uğur, Özdoğan Öner, Çalışkan Serhat, Akşit Ercan, Yılmaz Ahmet Seyda, Aksakal Emrah, Şimşek Zeki, Efe Süleyman Çağan, Aktüre Gülşah, Böyük Ferit, Başaran Özcan, Ballı Mehmet, Aslan Ahmet Oğuz, Babur Güler Gamze, Batgerel Ulaankhuu, Özkalaycı Flora, Kaya Bedri Caner, Kanar Batur Gönenç, Karakayalı Muammer, Erdoğan Emrah, İş Gürkan, Kalkan Sedat, Demirel Sinan, Aksu Uğur, Güray Ümit, Baş Hasan Aydın, Gök Murat, Yılmaz Mehmet Fatih, Şimşek Barış, Kolak Zeynep, Öz Melih, Uluköksal Utku, Kuloğlu Hüseyin Emre, Çabuk Gizem, Köksal Fatma, Nizam Ahmet Cem, Çoldur Rabia, Şaylık Faysal, Tanboğa İbrahim Halil
Аннотация
METHODS: The TRAFFIC study is a national, prospective, multicenter, observational registry. The study aims to collect data from at least 1900 patients diagnosed with atrial fibrillation, with the participation of 40 centers from Türkiye. The following data will be collected from patients: baseline demographic characteristics, medical history, vital signs, symptoms of AF, ECG and echocardiographic findings, CHADS2-VASC2 and HAS-BLED (1-year risk of major bleeding) risk scores, interventional treatments, antithrombotic and antiarrhythmic medications, or other medications used by the patients. For patients who use warfarin, international normalized ratio levels will be monitored. Follow-up data will be collected at 6, 12, 18, and 24 months. Primary endpoints are defined as systemic embolism or major safety endpoints (major bleeding, clinically relevant nonmajor bleeding, and minor bleeding as defined by the International Society on Thrombosis and Hemostasis). The main secondary endpoints include major adverse cardiovascular events (systemic embolism, myocardial infarction, and cardiovascular death), all-cause mortality, and hospitalizations due to all causes or specific reasons.
RESULTS: The results of the 12-month follow-up of the study are planned to be shared by the end of 2023.
CONCLUSION: The TRAFFIC study will reveal the prevalence and incidence, demographic characteristics, and risk profiles of AF patients in Türkiye. Additionally, it will provide insights into how current treatments are reflected in this population. Furthermore, risk prediction modeling and risk scoring can be conducted for patients with AF.